Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Shares of Cassava Sciences (NASDAQ: SAVA ), which has an Alzheimer's drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH).

SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud

Cassava Sciences will form a committee to evaluate new probes by U.S. regulators and investigate two senior employees, it said on Monday, days after a medical professor linked to the company was charged with fraud.

Cassava Sciences forms internal panel after US probe into two employees

Cassava Sciences (NASDAQ: SAVA) stock price has become a fallen angel. Once a high popular stock, it has crashed by over 45% this year and by more than 90% from its all-time high, giving it a market cap of over $530 million.

Cassava Sciences stock forecast: is it safe to buy the SAVA dip?

Shares of biotech company Cassava Sciences Inc. plummeted on Friday after a federal grand jury indicted a onetime science advisor to Cassava and charged him with falsifying data to obtain millions of dollars in government funds — the latest drama for a company that has faced questions over its efforts to develop an experimental Alzheimer's disease drug.

Cassava Sciences shares fall after onetime advisor indicted on fraud charges

A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.

Cassava Sciences Shares Plunge on Indictment Against Former Advisor

AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university's medical school as well as a former paid science advisor to Cassava Sciences.

Cassava Sciences Issues Statement on Former Science Advisor

CRISPR Therapeutics

Ginkgo Bioworks Holdings

In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.

Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich

Vale S.A.

This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks presenting an interesting buying opportunity: Cassava Sciences Inc  (NASDAQ:SAVA) and Vale SA (NYSE:VALE).

2 Stocks Under $20 for Investors to Watch

After reaching an important support level, Cassava Sciences, Inc. (SAVA) could be a good stock pick from a technical perspective. SAVA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross

AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $45 million, driven primarily by expenses for our clinical program in Alzheimer's disease.

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Annovis Bio

Anavex Life Sciences

Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.

Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box

Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised by NASDAQ that end-of-day (“EOD”) tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ. After EOD May 2, the Company expects NASDAQ to no longer accept or execute any trade for SAVAW warrants.

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

Ironwood Pharma

Nano-X Imaging

Investing in the biotech sphere isn't for the faint of heart, and you should steer clear of the biotech stocks to avoid. That's because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of Cassava Sciences' common stock per Warrant, for an effective price of approximately $22.00 per share.

Redemption Date Announced for Warrants

LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

APRIL 2 FINAL DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 29, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 27, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and October 12, 2023, both dates inclusive (the "Class Period") of the important April 2, 2024 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA

LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

News for Cassava Sciences Inc Stock (SAVA)